Table 1.
JAK2V617F associations in PV and CH
| PV JAK2V617F VAF |
CH JAK2V617F VAF |
|||
|---|---|---|---|---|
| <50% | >50% | <1% | >1% | |
| Quantitative | ||||
| WBC, ×109/L | 9.335 | 12.435 | 7.823 | 8.723 |
| Hg, g/dL | 14.635 | 15.935 | 14.223 | 14.323 |
| Platelets, ×109/L | 57135 | 49035 | 26423 | 36123 |
| Qualitative | ||||
| Venous thrombosis risk ratio | 1.035,∗ | 2.9735,∗ | 1.023† | 3.023† |
| CRP, mg/L | 27% > 336 | 63% > 336 | 2.223 | 2.823 |
| LDH, U/L | 30412 | 48012 | ||
| PRV-1 (CD177) expression, fold upregulation | 2012 | 57612 | ||
| Clonal expansion | ||||
| Splenomegaly prevalence | 12%12 | 91%12 | ||
| Red cell mass (% of normal) | 150%37‡ | 180%37‡ | ||
| CD34 circulation, ×106/L | 312 | 612 | ||
| 15-year myelofibrosis free survival | 100%11 | 40%11 | ||
CH, clonal hematopoiesis; CRP, C-reactive protein; LDH, lactate dehydrogenase; PRV-1, polycythemia rubra vera gene 1; WBC, white blood cell counts.
∗
Subhazard ratio in adjusted model.
†
Odds ratio in adjusted model; values in bold demonstrated statistical significance.
‡
Estimate made based on highly significant linear correlation.